Syngene Extends Long-Standing Research Partnership With Bristol Myers Squibb to 2035

Syngene Extends Long-Standing Research Partnership With Bristol Myers Squibb to 2035

By, Admin 22 January 2026

Syngene International has extended its long-term research collaboration with Bristol Myers Squibb (BMS) through 2035, reinforcing a partnership that spans more than two decades.

The renewed agreement expands the scope of collaboration across the entire drug development lifecycle, from early discovery to commercial support.

What the extended collaboration covers?

Under the new term, Syngene will continue to provide integrated, end-to-end services to BMS, including:

  • Discovery and translational sciences
  • Pharmaceutical development
  • Manufacturing support
  • Clinical trial enablement
  • Data, digital, and IT services

The goal is simple: faster program progression, smoother handoffs, and long-term capacity planning.

A partnership built over 25+ years

The Syngene–BMS relationship began in 1998 and led to the creation of the Biocon Bristol Myers Squibb Research and Development Center (BBRC).

Key milestones:

  • BBRC became Syngene’s first dedicated R&D centre
  • Fully operational since 2009
  • Now a core strategic R&D site for BMS

Today, the centre employs around 700 Syngene scientists working closely with BMS teams.

Scientific scope and therapeutic focus

BBRC supports a wide range of research and development activities, including:

  • Target identification and validation
  • Lead discovery and optimisation
  • Molecular and cell biology
  • Protein sciences and assay biology
  • Pharmaceutical development
  • Clinical biomarker research

These capabilities support BMS programmes across:

  • Cardiovascular disease
  • Fibrosis
  • Immunology
  • Oncology

Impact on BMS’ pipeline

Over the years, BBRC has helped advance multiple compounds from early discovery into first-in-human studies.

The collaboration has delivered:

  • Shorter development timelines
  • Lower overall R&D costs
  • Strong support for patent generation

Why this extension matters?

The agreement signals a shift from project-based outsourcing to long-term strategic partnership.

For Syngene, it reinforces its position as:

  • A global contract research and manufacturing partner
  • A provider of integrated discovery-to-commercial solutions
  • A long-term capacity and innovation partner for big pharma

For BMS, it ensures continuity, scale, and deep scientific integration to support future pipeline growth.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!